Macrophage migration inhibitory factor expression in ovarian cancer

American Journal of Obstetrics and Gynecology

Volumn 196, Issue 4, 2007, Pages 348.e1-348.e5

  Agarwal, Rinki ^a   Whang, Dong Hee ^b   Alvero, Ayesha B ^a   Visintin, Irene ^a   Lai, Yinglei ^c   Segal, Elliot A ^d   Schwartz, Peter ^a   Ward, David ^e   Rutherford, Thomas ^a   Mor, Gil ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Inje University College of Medicine   (South Korea)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d Onco Detectors International LLC   (United States)

^e Nevada Cancer Center   (United States)

Author keywords

inflammation and cancer; MIF; ovarian cancer

Indexed keywords

LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE MIGRATION INHIBITION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SURFACE PROPERTY;

EID: 33947623060     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2006.12.030     Document Type: Article

References (29)

1. Jemal A., Ward E., Hao Y., and Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 294 (2005) 1255-1259
2. Riman T., Dickman P.W., Nilsson S., Nordlinder H., Magnusson C.M., and Persson I.R. Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women. Eur J Epidemiol 19 (2004) 1011-1019
3. Balkwill F., and Coussens L.M. Cancer: an inflammatory link. Nature 431 (2004) 405-406
4. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
5. Robinson S.C., and Coussens L.M. Soluble mediators of inflammation during tumor development. Adv Cancer Res 93 (2005) 159-187
6. Mitchell R.A., and Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol 10 (2000) 359-366
7. Wilson J.M., Coletta P.L., Cuthbert R.J., et al. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129 (2005) 1485-1503
8. Hagemann T., Wilson J., Kulbe H., et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175 (2005) 1197-1205
9. Hudson J.D., Shoaibi M.A., Maestro R., Carnero A., Hannon G.J., and Beach D.H. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190 (1999) 1375-1382
10. Petrenko O., and Moll U.M. Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell 17 (2005) 225-236
11. Mitchell R.A., Liao H., Chesney J., et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A 99 (2002) 345-350
12. Kelly M.G., Alvero A.B., Chen R., et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66 (2006) 3859-3868
13. Behrens B.C., Hamilton T.C., Masuda H., et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47 (1987) 414-418
14. Kamsteeg M., Rutherford T., Sapi E., et al. Phenoxodiol-an isoflavon analogue-induces apoptosis in chemo-resistant ovarain cancer cells. Oncogene 22 (2003) 2611-2620
15. Alvero A.B., Fishman D.A., Qumsiyeh M.B., Garg M., Kacinski B.M., and Sapi E. Telomerase prolongs the lifespan of normal human ovarian surface epithelial cells without inducing neoplastic phenotype. J Soc Gynecol Investig 11 (2004) 553-561
16. Alvero A.B., O'Malley D., Brown D., et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 106 (2006) 599-608
17. Roger T., David J., Glauser M.P., and Calandra T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414 (2001) 920-924
18. Wilson G.L., and Young B.G. Production of migration inhibitory factor (MIF) by human leukocytes following exposure to Epstein-Barr virus. Cell Immunol 38 (1978) 147-156
19. Morand E.F., and Leech M. Macrophage migration inhibitory factor in rheumatoid arthritis. Front Biosci 10 (2005) 12-22
20. Leech M., Metz C., Hall P., et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42 (1999) 1601-1608
21. Denkinger C.M., Metz C., Fingerle-Rowson G., Denkinger M.D., and Forsthuber T. Macrophage migration inhibitory factor and its role in autoimmune diseases. Arch Immunol Ther Exp (Warsz) 52 (2004) 389-400
22. Bernhagen J., Bacher M., Calandra T., et al. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med 183 (1996) 277-282
23. Calandra T., Bernhagen J., Mitchell R.A., and Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179 (1994) 1895-1902
24. Hattori M., Nikolic-Paterson D.J., Miyazaki K., et al. Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney Int 71 Suppl (1999) S47-S50
25. Lan H.Y., Yang N., Nikolic-Paterson D.J., et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 57 (2000) 499-509
26. de Jong Y.P., Abadia-Molina A.C., Satoskar A.R., et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2 (2001) 1061-1066
27. Kats R., Metz C.N., and Akoum A. Macrophage migration inhibitory factor is markedly expressed in active and early-stage endometriotic lesions. J Clin Endocrinol Metab 87 (2002) 883-889
28. Leng L., Metz C.N., Fang Y., et al. MIF signal transduction initiated by binding to CD74. J Exp Med 197 (2003) 1467-1476
29. Mor G., Visintin I., Lai Y., et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102 (2005) 7677-7682